Atopic dermatitis market to hit $5.6 billion by 2022 in major countries

New market research titled "EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2024" says atopic dermatitis therapeutic sales in the nine major markets (9MM) are forecast to increase to $5.6 billion by 2022, at a compound annual growth rate (CAGR) of 3.8%.

Epidemiologists forecast that the one-year total prevalent cases of atopic dermatitis in the 9MM will increase from 66,289,178 cases in 2014 to 67,630,097 cases in 2024 with an annual growth rate (AGR) of 0.20% and the prevalent cases of atopic dermatitis in the 9MM from 2014-2024 using country-specific studies that provided one-year total prevalence of atopic dermatitis in these markets obtained through symptom-based surveys.

Atopic dermatitis or atopic eczema is the most common type of eczema. Atopic dermatitis is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. Though the condition affects people of all ages, it is primarily common among infants and children. Risk factors for atopic dermatitis are broadly classified as modifiable and non-modifiable. Modifiable risk factors include inhalant allergens, food allergens, and newborns not being exclusively breastfed; non-modifiable risk factors include young age and genetics or heritability. In addition, the most common co-morbidities associated with the atopic dermatitis such as atopic disorders and psychological disorders contribute significantly to the clinical occurrence of atopic dermatitis.